

Table 2: Change in clinical outcome (weight gain and FEV₁) and quality of life (QoL) score after intravenous antibiotic treatment of the 35 stable pediatric patients with cystic fibrosis that participated in this prospective study. Both groups show significant improvement in weight gain, FEV₁, and QOL. Hospital treatment showed a higher improvement in QoL, compared to home treatment.

Change in clinical outcome after iv treatment							
	Whole study group n =35		Group A (Home care) n =20		Group B (Hospital) n =15		Group A vs Group B
	Change after iv	p value whole study group	Change after iv	p value Group A	Change after iv	p value Group B	p value Group A vs Group B
ΔWeight, kg	1.2 (± 0.8)	0.001†	1.1 (±0.8)	0.001†	1.5 (±0.7)	0.001†	0.608
ΔFEV₁ (%)	7.7 (± 6.1)	0.001†	7.0 (±6.0)	0.001†	9.0 (±5.4)	0.001†	0.606
ΔQoL score	6.1 (± 3.9)	0.001†	7.4 (±3.7)	0.001†	3.8 (±2.6)	0.07	0.04*

Values are given as mean (± standard deviation in brackets), IV: intravenous, QoL: quality of life, ΔWeight: weight gain, ΔFEV₁: % change of the Forced Expiratory Volume in one second, ΔQoL: change in total QoL score, †: p ≤0.001, *: p <0.05.